---
document_datetime: 2025-01-08 16:36:56
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.0071908
conversion_datetime: 2025-12-27 14:56:13.92642
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Wegovy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1792              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                    | 14/10/2024                          |                                             | SmPC and PL                      |           |
| II/0021              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/10/2024                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0019   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                | 19/09/2024   |            | SmPC, Labelling and PL   |                                                                                                                                                                          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0022   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                | 05/09/2024   |            | SmPC and PL              |                                                                                                                                                                          |
| IB/0023   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                      | 30/08/2024   | n/a        |                          |                                                                                                                                                                          |
| II/0017   | Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from study EX9536-4388 (SELECT); this is a randomised, double-blind, placebo-controlled, trial comparing semaglutide 2.4 mg with placebo both administered s.c. once weekly in subjects with established cardiovascular disease and overweight or obesity. The Package Leaflet is updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 25/07/2024   |            | SmPC and PL              | Please refer to Scientific Discussion 'Wegovy-H-C-005422- II-0017'.                                                                                                      |
| X/0016    | Annex I_1.(c) Replacement of a biological AS with one of a slightly different molecular structure                                                                                                                                                                                                                                                                                                                                                                                                                | 25/04/2024   | 10/06/2024 | SmPC                     | Please refer to the scientific discussion EMEA/H/C/005422/X/0016                                                                                                         |
| II/0020/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/04/2024   | 10/06/2024 | SmPC, Labelling and      | SmPC Sections 2, 6.5 and 8 are being updated to include a new 0.5 mg pen variant of 0.68 mg/ml in a 3 ml cartridge (glass) in pre-filled pen (FlexTouch) for the sterile |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including   |            |            | PL                    | parenteral biological medicinal product Wegovy, 0.5 mg solution for injection, 1 pre-filled pen + 4 needles (EU/1/21/1608/012). The labelling and Package Leaflet are updated accordingly.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10671 /202305 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/01/2024 | 21/03/2024 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10671/202305.                                                   |
| II/0018             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 25/01/2024 | 21/03/2024 | SmPC and PL           |                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IB/0015/G   | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                    | 11/10/2023   | 21/03/2024   | Annex II and PL   |                     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|---------------------|
| WS/2494/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.z - Quality change - Active substance - Other | 31/08/2023   | n/a          |                   | variation           |
| IB/0012     | B.II.g.4.b - Changes to an approved change - Minor changes that do not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 04/05/2023   | n/a          |                   | management protocol |

<div style=\"page-break-after: always\"></div>

|                     | change the strategy defined in the protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009             | Extension of indication to include treatment of adolescents for weight management based on the final results from study NN9536-4451; this trial was conducted to assess the efficacy and safety of semaglutide in paediatric patients of age 12 to <18 years with obesity. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP was agreed during the procedure. Furthermore, the PI is brought in line with the latest QRD template version 10.2. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 30/03/2023 | 28/04/2023 | SmPC and PL | Please refer to Scientific Discussion 'Wegovy-H-C-005422- II-0009'                                                                                             |
| PSUSA/10671 /202205 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/01/2023 | 31/03/2023 | SmPC and PL | Please refer to semaglutide PSUSA/10671/202205 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IA/0011             | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10/01/2023 | n/a        |             |                                                                                                                                                                |
| IB/0010             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/01/2023 | n/a        |             |                                                                                                                                                                |
| II/0003/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/07/2022 | 31/03/2023 | SmPC        | In STEP 5 trial, treatment with semaglutide for 104 weeks                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | Update of section 5.1 of the SmPC in order to update the description of the pharmacodynamic effects and clinical efficacy and safety based on final results from interventional studies: Trial 4378 (STEP 5) which compared the two-year effect of semaglutide 2.4 mg once weekly versus placebo; Trial 4576 (STEP 8) which compared semaglutide s.c. 2.4 mg once weekly to liraglutide s.c. 3.0 mg once daily and Trial 4373 extension (STEP 1ext) which explored the change in body weight, cardiovascular risk factors and glucose metabolism in subjects who completed 68 weeks of treatment (semaglutide 2.4 mg or placebo) followed by a 52-week off-treatment period. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to   |            |     | resulted in a significantly higher reduction in body weight compared to placebo. In STEP 8 trial, treatment with semaglutide once weekly for 68 weeks resulted in significantly higher reduction in body weight compared to daily liraglutide. In STEP 1ext trial, in the 52-week off- treatment period from week 68 to week 120, mean body weight increased lower in semaglutide than in the placebo treatment group. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/07/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/10671 /202111 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/07/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0001/G   | This was an application for a group of variations. B.IV.1.a.1 - Change of a measuring or administration   | 23/06/2022   | 31/03/2023   | SmPC, Labelling and PL   |
|-------------|-----------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0006/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/05/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|         | (including replacement or addition)                                                                                                                                            |            |     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0005 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 20/04/2022 | n/a |
| IA/0004 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                               | 14/03/2022 | n/a |